CA2468552A1 - 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof - Google Patents
3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof Download PDFInfo
- Publication number
- CA2468552A1 CA2468552A1 CA002468552A CA2468552A CA2468552A1 CA 2468552 A1 CA2468552 A1 CA 2468552A1 CA 002468552 A CA002468552 A CA 002468552A CA 2468552 A CA2468552 A CA 2468552A CA 2468552 A1 CA2468552 A1 CA 2468552A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- groups
- independently
- unsubstituted alkyl
- chnh2r4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Joints Allowing Movement (AREA)
Abstract
The invention is directed to 3-.beta.-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
Claims (11)
1. ~A compound represented by Formula I:
wherein:
R1 is independently H, -C(O)R3, or a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R3 is a substituted or unsubstituted alkyl, and R4 is H, or a substituted or unsubstituted alkyl;
R2 is H, OR5, or N(R6)2, wherein R5 is independently H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring; and wherein if R2 is -OH, at least one of the R1 groups is a racemic, L-, or D-amino acid group -C(O)CHNH2R4;
or a pharmaceutically acceptable salt.
wherein:
R1 is independently H, -C(O)R3, or a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R3 is a substituted or unsubstituted alkyl, and R4 is H, or a substituted or unsubstituted alkyl;
R2 is H, OR5, or N(R6)2, wherein R5 is independently H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring; and wherein if R2 is -OH, at least one of the R1 groups is a racemic, L-, or D-amino acid group -C(O)CHNH2R4;
or a pharmaceutically acceptable salt.
2. ~The compound or pharmaceutically acceptable salt according to claim 1, wherein at least one of the R1 groups is a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R5 is independently selected from H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring.
3. ~The compound or pharmaceutically acceptable salt according to claim 2, wherein at least one of the R1 groups is a L- amino acid group -C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining groups are H; R2 is OR5 or N(R6)2, wherein R4 is a substituted alkyl, and wherein R6 is independently H or substituted or unsubstituted alkyl.
4. The compound or pharmaceutically acceptable salt according to claim 3, wherein at least one of the R1 groups is a L- amino acid group -C(O)CHNH2R4, wherein R4 is -CH(CH3)2, and wherein the remaining R1 groups are H; and R2 is OH.
5. The compound or pharmaceutically acceptable salt according to claim 1, selected from the group consisting of:
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by Formula I:
wherein:
R1 is independently H, -C(O)R3, or a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R3 is a substituted or unsubstituted alkyl, and R4 is H, or a substituted or unsubstituted alkyl;
R2 is H, OR5, or N(R6)2, wherein R5 is independently H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring; and wherein if R2 is -OH, at least one of the R1 groups is a racemic, L-, or D-amino acid group -C(O)CHNH2R4;
or a pharmaceutically acceptable salt.
wherein:
R1 is independently H, -C(O)R3, or a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R3 is a substituted or unsubstituted alkyl, and R4 is H, or a substituted or unsubstituted alkyl;
R2 is H, OR5, or N(R6)2, wherein R5 is independently H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring; and wherein if R2 is -OH, at least one of the R1 groups is a racemic, L-, or D-amino acid group -C(O)CHNH2R4;
or a pharmaceutically acceptable salt.
7. The pharmaceutical composition according to claim 6, wherein at least one of the R1 groups is a racemic, L-, or D- amino acid group -C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R5 is independently selected from H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring.
8. The pharmaceutical composition according to claim 7, wherein at least one of the R1 groups is a L- amino acid group -C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H;
R2 is OR5 or N(R6)2, wherein R4 is a substituted alkyl, and wherein R6 is independently H
or substituted or unsubstituted alkyl.
R2 is OR5 or N(R6)2, wherein R4 is a substituted alkyl, and wherein R6 is independently H
or substituted or unsubstituted alkyl.
9. The pharmaceutical composition according to claim 8, wherein at least one of the R1 groups is a L- amino acid group -C(O)CHNH2R4, wherein R4 is -CH(CH3)2, and wherein the remaining R1 groups are H; and R2 is OH.
10. The pharmaceutical composition according to claim 6 that is selected from the group consisting of:
11. A method of modulating immune cytokine activities in a patient comprising:
providing a compound or pharmaceutically acceptable salt of formula I
according to claim 1; and treating a patient in need thereof with the compound or pharmaceutically acceptable salt.
providing a compound or pharmaceutically acceptable salt of formula I
according to claim 1; and treating a patient in need thereof with the compound or pharmaceutically acceptable salt.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33346001P | 2001-11-27 | 2001-11-27 | |
| US60/333,460 | 2001-11-27 | ||
| PCT/US2002/038001 WO2003045968A1 (en) | 2001-11-27 | 2002-11-27 | 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2468552A1 true CA2468552A1 (en) | 2003-06-05 |
| CA2468552C CA2468552C (en) | 2011-09-20 |
Family
ID=23302891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2468552A Expired - Fee Related CA2468552C (en) | 2001-11-27 | 2002-11-27 | 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6924271B2 (en) |
| EP (1) | EP1451203B1 (en) |
| JP (1) | JP4493337B2 (en) |
| KR (1) | KR100718371B1 (en) |
| CN (2) | CN101033242A (en) |
| AP (1) | AP2004003069A0 (en) |
| AT (1) | ATE448238T1 (en) |
| AU (1) | AU2002365412B2 (en) |
| BR (1) | BR0214407A (en) |
| CA (1) | CA2468552C (en) |
| CO (1) | CO5590931A2 (en) |
| DE (1) | DE60234376D1 (en) |
| EA (1) | EA008380B1 (en) |
| EC (1) | ECSP045167A (en) |
| ES (1) | ES2333945T3 (en) |
| GE (1) | GEP20074099B (en) |
| HR (1) | HRP20040541A2 (en) |
| IL (1) | IL162137A0 (en) |
| IS (1) | IS7283A (en) |
| MA (1) | MA27156A1 (en) |
| MX (1) | MXPA04004966A (en) |
| NO (1) | NO20042676L (en) |
| NZ (1) | NZ533628A (en) |
| OA (1) | OA12729A (en) |
| TN (1) | TNSN04113A1 (en) |
| UA (1) | UA79764C2 (en) |
| WO (1) | WO2003045968A1 (en) |
| YU (1) | YU45204A (en) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| ES2541132T3 (en) * | 2002-02-22 | 2015-07-16 | Meda Ab | Method to reduce and treat UV-B-induced immunosuppression |
| CA2511538C (en) * | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US7375180B2 (en) * | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
| EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
| CA2517528A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
| CA2518282C (en) * | 2003-03-13 | 2012-11-06 | 3M Innovative Properties Company | Methods of improving skin quality |
| AU2004220465A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
| US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20040202720A1 (en) * | 2003-04-10 | 2004-10-14 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
| US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| CA2534042A1 (en) * | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
| TW200510412A (en) | 2003-08-12 | 2005-03-16 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
| JP2007504145A (en) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Immunostimulatory combinations and treatments |
| CA2536136C (en) | 2003-08-27 | 2012-10-30 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
| JP2007504269A (en) | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
| EP1664342A4 (en) * | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | Selective modulation of tlr gene expression |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| JP5043435B2 (en) | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | Alkoxy substituted imidazoquinolines |
| AU2004285575A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
| CN1906193A (en) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Oxime substituted imidazo ring compounds |
| AU2004291122A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| AR046781A1 (en) | 2003-11-25 | 2005-12-21 | 3M Innovative Properties Co | IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS. |
| EP1689361A4 (en) * | 2003-12-02 | 2009-06-17 | 3M Innovative Properties Co | Therapeutic combinations and methods including irm compounds |
| US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| WO2005066169A2 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| EP1735010A4 (en) * | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | Methods, compositions, and preparations for delivery of immune response modifiers |
| JP2008505857A (en) * | 2004-04-28 | 2008-02-28 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for mucosal vaccination |
| US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
| US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
| CN1964985A (en) * | 2004-06-07 | 2007-05-16 | 阿纳迪斯药物公司 | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
| US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US20060045886A1 (en) * | 2004-08-27 | 2006-03-02 | Kedl Ross M | HIV immunostimulatory compositions |
| JP2008515928A (en) * | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Adjuvants for DNA vaccines |
| CN102504001B (en) * | 2004-12-17 | 2015-02-25 | 安那迪斯药品股份有限公司 | 3, 5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
| US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
| JP2008526765A (en) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
| WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| JP2008530113A (en) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods |
| EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| SG164344A1 (en) | 2005-02-18 | 2010-09-29 | Novartis Vaccines & Diagnostics Srl | Immunogens from uropathogenic escherichia coli |
| US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
| US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
| EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
| KR20080059270A (en) * | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
| CA2623864C (en) | 2005-09-30 | 2014-12-16 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection |
| EP1945252B1 (en) | 2005-11-04 | 2013-05-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene |
| PT1951299E (en) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| CA2628206A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
| JP5117391B2 (en) | 2005-11-21 | 2013-01-16 | アナディス ファーマシューティカルズ インク | Novel process for preparing 5-amino-3H-thiazolo [4,5-d] pyrimidin-2-one |
| JP6087041B2 (en) | 2006-01-27 | 2017-03-08 | ノバルティス アーゲー | Influenza virus vaccine containing hemagglutinin and matrix protein |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| WO2007109810A2 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
| CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| CA2646539A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| EP2382988A1 (en) | 2006-03-31 | 2011-11-02 | Novartis AG | Combined mucosal and parenteral immunization against HIV |
| CN101466727B (en) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv inhibitor and their uses |
| AR061024A1 (en) * | 2006-05-22 | 2008-07-30 | Novartis Ag | MALEATE OF 5-AMINO-3- (2'3'-DI-O-ACETYL-BETA-D-RIBOFURANOSIL) -3H-TIAZOLO [4,5-D] PYRIMIDIN-2-ONA. |
| ATE522541T1 (en) | 2006-06-09 | 2011-09-15 | Novartis Ag | BACTERIAL ADHESIN CONFORMERS |
| TWI418561B (en) | 2006-06-22 | 2013-12-11 | Anadys Pharmaceuticals Inc | Prodrugs of 5-amino-3-(3'-deoxy-β-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| US7528115B2 (en) | 2006-07-18 | 2009-05-05 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| ES2536401T3 (en) | 2006-09-11 | 2015-05-25 | Novartis Ag | Making vaccines against influenza viruses without using eggs |
| BRPI0717741A2 (en) * | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | PREPARATION METHODS, METHOD OF PREPARATION, SUBSTITUTED SULFONIL COMPOUND REDUCTION METHOD, PHARMACEUTICAL COMPOSITION TREATMENT OR DISEASE PREVENTION |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| KR100880298B1 (en) * | 2006-12-06 | 2009-01-28 | 애나디스 파마슈티칼스, 인코포레이티드 | 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
| ES2480491T3 (en) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vaccines including four influenza virus strains antigen |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| US20080255038A1 (en) * | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
| BRPI0813866A2 (en) | 2007-06-27 | 2015-01-06 | Novartis Ag | VACCINES AGAINST INFLUENCE WITH LOW ADDITIVE CONTENT |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| WO2009026292A1 (en) * | 2007-08-20 | 2009-02-26 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| JP5518041B2 (en) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | Improvements in the preparation of influenza virus vaccine antigens |
| WO2010002428A2 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
| WO2009148615A1 (en) * | 2008-06-06 | 2009-12-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
| US8536114B2 (en) * | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
| EP3549602A1 (en) | 2009-03-06 | 2019-10-09 | GlaxoSmithKline Biologicals S.A. | Chlamydia antigens |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| SI2510947T1 (en) | 2009-04-14 | 2016-05-31 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against Staphylococcus aureus |
| KR20120027276A (en) | 2009-04-27 | 2012-03-21 | 노파르티스 아게 | Adjuvanted vaccines for protecting against influenza |
| CA2767536A1 (en) | 2009-07-07 | 2011-01-13 | Novartis Ag | Conserved escherichia coli immunogens |
| BR112012001666A2 (en) | 2009-07-15 | 2019-09-24 | Novartis Ag | rsv f protein compositions and methods for making the same |
| JP2012532626A (en) | 2009-07-16 | 2012-12-20 | ノバルティス アーゲー | Detoxified Escherichia coli immunogen |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| CN102869367A (en) | 2009-12-09 | 2013-01-09 | 西尼克斯公司 | Novel cyclic peptides |
| ES2707778T3 (en) | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Immunogens polysaccharides conjugated with carrier proteins of E. coli |
| KR20130121699A (en) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | Interactive hybrid asynchronous computer game infrastructure |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
| SI2667892T1 (en) | 2011-01-26 | 2019-05-31 | Glaxosmithkline Biologicals Sa | Rsv immunization regimen |
| CN102153548B (en) * | 2011-02-24 | 2012-11-28 | 河北大学 | Analogue nucleoside derivative containing thiazolidone (thiazinidone) ring, preparation method and application thereof to medicinal preparations |
| ES2651143T3 (en) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | RS prefusion F antigens |
| JP6460789B2 (en) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker |
| BR112013031039B1 (en) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate |
| US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
| CN104080479B (en) | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | Carrier molecules including spr0096 and spr2021 antigen |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
| WO2014053521A2 (en) | 2012-10-02 | 2014-04-10 | Novartis Ag | Nonlinear saccharide conjugates |
| CN111249455A (en) | 2012-11-30 | 2020-06-09 | 葛兰素史密丝克莱恩生物有限公司 | Pseudomonas antigens and antigen combinations |
| MX2015008773A (en) | 2013-01-07 | 2015-11-06 | Univ Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma. |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
| DK3166976T3 (en) | 2014-07-09 | 2022-04-11 | Birdie Biopharmaceuticals Inc | ANTI-PD-L1 COMBINATIONS FOR TREATMENT OF TUMORS |
| CN105233291A (en) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | Combined therapy composition and combined therapy method for treating cancers |
| CN112587672A (en) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | anti-PD-L1 conjugates for the treatment of tumors |
| WO2017048807A1 (en) | 2015-09-17 | 2017-03-23 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration or moisturization |
| WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
| CN115554406A (en) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | anti-CD 20 combinations for the treatment of tumors |
| CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | Anti-EGFR for treating tumour is combined |
| CN115350279A (en) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | anti-HER 2 combinations for the treatment of tumors |
| CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
| BR112019027025A2 (en) | 2017-06-23 | 2020-06-30 | Birdie Biopharmaceuticals, Inc. | pharmaceutical compositions |
| CA3034912A1 (en) | 2018-02-28 | 2019-08-28 | Pfizer Inc. | Il-15 variants and uses thereof |
| EP3796983A2 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
| TWI793325B (en) | 2018-05-23 | 2023-02-21 | 美商輝瑞大藥廠 | Antibodies specific for cd3 and uses thereof |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
| TW202216779A (en) | 2020-07-17 | 2022-05-01 | 美商輝瑞股份有限公司 | Therapeutic antibodies and their uses |
| WO2023196458A1 (en) * | 2022-04-06 | 2023-10-12 | VenatoRx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4746651A (en) | 1983-11-01 | 1988-05-24 | Scripps Clinic And Research Foundation | Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives |
| GB8712745D0 (en) | 1987-05-30 | 1987-07-01 | Wellcome Found | Antiviral compounds |
| US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
| GB9015914D0 (en) | 1990-07-19 | 1990-09-05 | Wellcome Found | Heterocyclic compounds |
| US5248672A (en) | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
| GB9105899D0 (en) | 1991-03-20 | 1991-05-08 | Wellcome Found | Therapeutic nucleosides |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| CA2266889A1 (en) * | 1996-10-16 | 1998-04-23 | Guangyi Wang | Purine l-nucleosides, analogs and uses thereof |
| US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
| US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
-
2002
- 2002-11-27 CN CNA2006101728401A patent/CN101033242A/en active Pending
- 2002-11-27 OA OA1200400146A patent/OA12729A/en unknown
- 2002-11-27 DE DE60234376T patent/DE60234376D1/en not_active Expired - Lifetime
- 2002-11-27 AU AU2002365412A patent/AU2002365412B2/en not_active Ceased
- 2002-11-27 AT AT02804071T patent/ATE448238T1/en not_active IP Right Cessation
- 2002-11-27 YU YU45204A patent/YU45204A/en unknown
- 2002-11-27 CN CNB028268040A patent/CN1300165C/en not_active Expired - Fee Related
- 2002-11-27 NZ NZ533628A patent/NZ533628A/en unknown
- 2002-11-27 MX MXPA04004966A patent/MXPA04004966A/en active IP Right Grant
- 2002-11-27 ES ES02804071T patent/ES2333945T3/en not_active Expired - Lifetime
- 2002-11-27 CA CA2468552A patent/CA2468552C/en not_active Expired - Fee Related
- 2002-11-27 IL IL16213702A patent/IL162137A0/en unknown
- 2002-11-27 EA EA200400735A patent/EA008380B1/en not_active IP Right Cessation
- 2002-11-27 GE GE5620A patent/GEP20074099B/en unknown
- 2002-11-27 US US10/305,061 patent/US6924271B2/en not_active Expired - Lifetime
- 2002-11-27 WO PCT/US2002/038001 patent/WO2003045968A1/en active Application Filing
- 2002-11-27 UA UA20040604959A patent/UA79764C2/en unknown
- 2002-11-27 JP JP2003547417A patent/JP4493337B2/en not_active Expired - Fee Related
- 2002-11-27 KR KR1020047008062A patent/KR100718371B1/en not_active IP Right Cessation
- 2002-11-27 EP EP02804071A patent/EP1451203B1/en not_active Expired - Lifetime
- 2002-11-27 BR BR0214407-7A patent/BR0214407A/en not_active IP Right Cessation
- 2002-11-27 AP APAP/P/2004/003069A patent/AP2004003069A0/en unknown
-
2004
- 2004-05-21 IS IS7283A patent/IS7283A/en unknown
- 2004-06-14 HR HR20040541A patent/HRP20040541A2/en not_active Application Discontinuation
- 2004-06-15 TN TNP2004000113A patent/TNSN04113A1/en unknown
- 2004-06-15 MA MA27735A patent/MA27156A1/en unknown
- 2004-06-18 CO CO04057566A patent/CO5590931A2/en not_active Application Discontinuation
- 2004-06-22 EC EC2004005167A patent/ECSP045167A/en unknown
- 2004-06-25 NO NO20042676A patent/NO20042676L/en not_active Application Discontinuation
-
2005
- 2005-03-16 US US11/080,449 patent/US20050182001A1/en not_active Abandoned
-
2007
- 2007-02-22 US US11/709,129 patent/US20080090844A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2468552A1 (en) | 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | |
| CA1266473A (en) | Benzoyl urea compounds, useful as anti-tumor drugs | |
| CA2312885A1 (en) | 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof | |
| EP0368640A3 (en) | Heterocyclic compounds | |
| CA2334342A1 (en) | Epothilone derivatives and their synthesis and use | |
| CA2531732A1 (en) | Prodrugs of 9-aminomethyl tetracycline compounds | |
| CA2261886A1 (en) | Peptidyl prodrugs and methods of making and using the same | |
| HUP0402489A2 (en) | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | |
| EP0899263A3 (en) | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | |
| RU2000128058A (en) | ECTEINASCIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND METHOD FOR TREATING TUMORS | |
| CA2015475A1 (en) | Treating agent for osteoarthritis | |
| HUT61780A (en) | Process for producing new peptides and pharmaceutical compositions comprising same as active ingredient | |
| CA2126118A1 (en) | 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative | |
| WO1993014767A3 (en) | Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections | |
| CA2566541A1 (en) | 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | |
| CA2010639A1 (en) | Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-thiones | |
| CA2295483A1 (en) | Aliphatic propargylamines as cellular rescue agents | |
| ATE72447T1 (en) | CHARTREUS INDIVIDUALS AND SALTS, ANTITUMOR COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION. | |
| CA2118425A1 (en) | Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof | |
| KR910018341A (en) | Novel α-mannosidase and fucosidase inhibitors | |
| CA2452920A1 (en) | Benzo [g] quinoline derivatives for treating glaucoma and myopia | |
| EP0997473A4 (en) | Natural antitumor or antiviral substances and use of the same | |
| CA2089207A1 (en) | Amphoteric Tricyclic Compound | |
| IL155656A (en) | Long-acting interferon and interleukin derivatives and pharmaceutical compositions comprising them | |
| HK1068344A1 (en) | Dimeric compounds and their use as anti-viral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20181127 |